Parameter Diagnose Specification Erenumab % Galcanezumab %
Sex CM Women 51 87,93 32 96,97
Men 7 12,07 1 3,03
EM Women 20 80,00 21 91,30
Men 5 20,00 2 8,70
Concomitant preventive treatment CM Yes 37 63,79 22,2 67,27
No 21 36,21 10,8 32,73
EM Yes 16 64,00 15,0 65,32
No 9 36,00 8,0 34,68
Preventive treatment therapeutic group CM Antiepileptic 10 27,03 9 40,54
Beta-blockers 15 40,54 12 54,05
Antidepressants 18 48,65 10 45,05
ARA-II 4 10,81 1 4,50
Calcium antagonists 0 0,00 1 4,50
EM Antiepileptic 4 25,00 6 39,94
Beta-blockers 4 25,00 4 26,62
Antidepressants 5 31,25 6 39,94
ARA-II 2 12,50 1 6,66
Calcium antagonists 2 12,50 0 0,00
Concomitant treatment with onabotulinumtoxinA CM Baseline 23 39,66 16 48,48
After 3 doses 23 39,66 14 42,42
After 6 doses 17 29,31 13 39,39
EM Baseline 10 40,00 13 56,52
After 3 doses 10 40,00 10 43,48
After 6 doses 7 28,00 9 39,13
Analgesic medication abuse CM Yes 39 67,24 28 84,85
No 19 32,76 5 15,15
EM Yes 4 16,00 16 69,57
No 21 84,00 7 30,43